Tourmaline Bio, Inc.
TRMLDelisted Oct 28, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827506
Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in Tourmaline Bio, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +2 vs. Q1 2025
- Shares held
- 24.1M
- +116.2K (+0.5%) vs. Q1 2025
- Total value
- $384.8M
- +$20.5M (+5.6%) vs. Q1 2025
- New holders
- 20
- 34 more added
- Sold out
- 18
- 31 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRML on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 134 | $1.03B |
| Q2 2025 | 109 | $384.8M |
| Q1 2025 | 107 | $364.3M |
| Q4 2024 | 101 | $463.6M |
| Q3 2024 | 92 | $540.7M |
| Q2 2024 | 84 | $272.0M |
| Q1 2024 | 96 | $469.9M |
| Q4 2023 | 54 | $338.2M |
| Q3 2023 | 49 | $77.1M |
| Q2 2023 | 58 | $79.7M |
| Q1 2023 | 54 | $50.6M |
| Q4 2022 | 54 | $27.4M |
| Q3 2022 | 56 | $72.1M |
| Q2 2022 | 59 | $130.4M |
| Q1 2022 | 51 | $286.9M |
| Q4 2021 | 51 | $456.7M |
| Q3 2021 | 48 | $349.4M |
| Q2 2021 | 50 | $379.4M |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Tourmaline Bio, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Octagon Capital Advisors LP | 905,000 | $14.5M | 3.18% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 997,107 | $15.9M | 5.15% | −40,000−3.9% | Reduced |
| Vanguard Group Inc | 1,207,035 | $19.3M | 0.00% | +16,225+1.4% | Added |
| Pfizer Inc | 1,272,214 | $20.3M | 3.53% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 1,477,593 | $23.6M | 2.70% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,633,942 | $26.1M | 0.00% | −158,266−8.8% | Reduced |
| QVT Financial LP | 2,154,653 | $34.5M | 4.81% | +681,284+46.2% | Added |
| Ra Capital Management, L.P. | 2,538,925 | $40.6M | 0.68% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 2,555,555 | $40.9M | 0.72% | +130,555+5.4% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −570,588−100.0% | Sold out |
| Nan Fung Group Holdings Ltd | 0 | $0 | 0.00% | −227,090−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −121,245−100.0% | Sold out |
| Jennison Associates LLC | 0 | $0 | 0.00% | −118,487−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −99,166−100.0% | Sold out |
| Wexford Capital LP | 0 | $0 | 0.00% | −63,610−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −36,643−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −20,893−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −17,860−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −14,312−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −12,219−100.0% | Sold out |
| Corebridge Financial, Inc. | 0 | $0 | 0.00% | −11,309−100.0% | Sold out |
| Intech Investment Management LLC | 0 | $0 | 0.00% | −10,583−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −10,357−100.0% | Sold out |
| Jones Financial Companies LLLP | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −54−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −43−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −7−100.0% | Sold out |